New drug combo shows promise for tough cancers

NCT ID NCT07644039

Recruiting now Disease control Sponsor: PharmaMar Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jul 31, 2026 · Updated 3 times

Summary

This study tests a new drug called PM54 combined with the immunotherapy pembrolizumab in adults with advanced cancers that have not responded to prior treatments. The goal is to find a safe dose and see if the combination can shrink tumors or stop them from growing. About 119 participants will be enrolled across multiple centers.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: PM54 (a new drug) combined with pembrolizumab (an immunotherapy)
What this could lead to: If successful, this could lead to a new treatment option for people with advanced cancers that have not responded to prior therapies.
What could go wrong: This is an early-phase trial with a small number of participants, so the drug combination may not prove effective or may cause unexpected side effects. Success in this trial does not guarantee future approval.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED MALIGNANCIES are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

cancer neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED MALIGNANCIES

Contacts and locations

Locations

Clinica Universidad de Navarra (CUN)
RECRUITING

Madrid, Spain
Clinica Universidad de Navarra (CUN)
RECRUITING

Pamplona, Spain
Hospital General Universitario Gregorio Marañón
RECRUITING

Madrid, Spain
Institut Català d'Oncologia
NOT_YET_RECRUITING

Barcelona, Spain
NEXT Dallas
RECRUITING

Irving, Texas, 75039, United States
NEXT Houston
RECRUITING

Houston, Texas, 77054, United States
NEXT Virginia
RECRUITING

Fairfax, Virginia, 22031, United States
START Dallas
RECRUITING

Fort Worth, Texas, 76104, United States
START Madrid - Hospital Universitario Fundacion Jimenez D
RECRUITING

Madrid, Spain
START New York
RECRUITING

New York, New York, 11042, United States
The University of Texas MD Anderson Cancer Center
RECRUITING

Houston, Texas, 77030, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.